» Articles » PMID: 37715239

Divergent Functions of NLRP3 Inflammasomes in Cancer: a Review

Overview
Publisher Biomed Central
Date 2023 Sep 15
PMID 37715239
Authors
Affiliations
Soon will be listed here.
Abstract

The cancer is a serious health problem, which is The cancer death rate (cancer mortality) is 158.3 per 100,000 men and women per year (based on 2013-2017 deaths). Both clinical and translational studies have demonstrated that chronic inflammation is associated with Cancer progression. However, the precise mechanisms of inflammasome, and the pathways that mediate this phenomenon are not fully characterized. One of the most recently identified signaling pathways, whose activation seems to affect many metabolic disorders, is the "inflammasome" a multiprotein complex composed of NLRP3 (nucleotide-binding domain and leucine-rich repeat protein 3), ASC (apoptosis associated speck-like protein containing a CARD), and procaspase-1. NLRP3 inflammasome activation leads to the processing and secretion of the proinflammatory cytokines interleukin-1β (IL-1β) and IL-18. The goal of this paper is to review new insights on the effects of the NLRP3 inflammasome activation in the complex mechanisms of crosstalk between different organs, for a better understanding of the role of chronic inflammation in cancer pathogenesis. We will provide here a perspective on the current research on NLRP3 inflammasome, which may represent an innovative therapeutic target to reverse the malignancy condition consequences of the inflammation. Video Abstract.

Citing Articles

The intervention of NLRP3 inflammasome inhibitor: oridonin against azoxymethane and dextran sulfate sodium-induced colitis-associated colorectal cancer in male BALB/c mice.

Kaur G, Tiwari P, Singla S, Panghal A, Jena G Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40035821 DOI: 10.1007/s00210-025-03871-z.


Natural and synthetic potential drug leads for rheumatoid arthritis probing innovative target: mitochondrial dysfunction and NLRP3 inflammasome activation.

Iqbal U, Malik A, Ibrahim L, Sial N, Mehmood M Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40019529 DOI: 10.1007/s00210-025-03897-3.


IL-1β in Neoplastic Disease and the Role of Its Tumor-Derived Form in the Progression and Treatment of Metastatic Prostate Cancer.

Oyende Y, Taus L, Fatatis A Cancers (Basel). 2025; 17(2).

PMID: 39858071 PMC: 11763358. DOI: 10.3390/cancers17020290.


A Narrative Review of Prognostic Gene Signatures in Oral Squamous Cell Carcinoma Using LASSO Cox Regression.

Mohd Faizal N, Shai S, Savaliya B, Karen-Ng L, Kumari R, Kumar R Biomedicines. 2025; 13(1).

PMID: 39857718 PMC: 11759772. DOI: 10.3390/biomedicines13010134.


Therapeutic Significance of NLRP3 Inflammasome in Cancer: Friend or Foe?.

Jalali A, Mitchell K, Pompoco C, Poludasu S, Tran S, Ramana K Int J Mol Sci. 2025; 25(24.

PMID: 39769450 PMC: 11728390. DOI: 10.3390/ijms252413689.


References
1.
Zheng D, Liwinski T, Elinav E . Inflammasome activation and regulation: toward a better understanding of complex mechanisms. Cell Discov. 2020; 6:36. PMC: 7280307. DOI: 10.1038/s41421-020-0167-x. View

2.
Sharma D, Kanneganti T . The cell biology of inflammasomes: Mechanisms of inflammasome activation and regulation. J Cell Biol. 2016; 213(6):617-29. PMC: 4915194. DOI: 10.1083/jcb.201602089. View

3.
Schroder K, Tschopp J . The inflammasomes. Cell. 2010; 140(6):821-32. DOI: 10.1016/j.cell.2010.01.040. View

4.
Man S . Inflammasomes in the gastrointestinal tract: infection, cancer and gut microbiota homeostasis. Nat Rev Gastroenterol Hepatol. 2018; 15(12):721-737. PMC: 7097092. DOI: 10.1038/s41575-018-0054-1. View

5.
Gultekin Y, Eren E, Ozoren N . Overexpressed NLRC3 acts as an anti-inflammatory cytosolic protein. J Innate Immun. 2014; 7(1):25-36. PMC: 6950940. DOI: 10.1159/000363602. View